Men with prostate cancer who were treated with the GnRH agonist leuprolide had significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix.

I f prostate cancer has spread to other areas of your body, your doctor may recommend androgen deprivation therapy (ADT), which halts the production of androgen hormones, especially testosterone.

Overall, serious adverse events occurred in 3.9% of patients over the 6-month study period. Use of relugolix among patients with prostate cancer is associated with stable quality of life (QoL), high ...

ADT speeds coronary atherosclerosis, with greater effects with use of the GnRH-agonist leuprolide compared with the GnRH-antagonist relugolix. Coronary atherosclerosis may progress more over 12 months ...

Efficacy of triplet therapy based on organoid drug sensitivity testing in lung metastatic hormone-sensitive prostate cancer. † Number of pts who were continuously prescribed relugolix tx during each ...

A dyadic exercise approach to prevent declines in physical and mental health in couples during radiation treatment for cancer: Protocol for a hybrid type I efficacy implementation trial. This is an ...

Two types of androgen deprivation therapy (ADT) had different effects on coronary atherosclerosis in a small randomized trial of men with prostate cancer. Significantly more coronary artery plaque ...